Magnetic Resonance Imaging Detects Early Changes in Microvascular Permeability in Xenograft Tumors after Treatment with the Matrix Metalloprotease Inhibitor Prinomastat
Free accessResearch articleFirst published online August, 2004
Magnetic Resonance Imaging Detects Early Changes in Microvascular Permeability in Xenograft Tumors after Treatment with the Matrix Metalloprotease Inhibitor Prinomastat
Macromolecular contrast medium-enhanced magnetic resonance imaging was applied to monitor the effect of matrix metalloprotease (MMP) inhibition on microvascular characteristics of human breast cancers implanted in athymic rats. Twice-daily intraperitoneal administration of Prinomastat over 1.5 days induced significant declines in MRI-assayed microvascular permeabilities (p<0.05); but this leak suppression effect had extinguished by the 10th day of MMP treatment using the same dose and time schedule. Results demonstrate that Prinomastat produces a rapid but transient decrease in tumor vascular permeability. Contrast-enhanced MRI using macromolecular contrast medium may prove useful as a biomarker for the dynamic MMP biological effect in cancers.
ChambersA. F.MatrisianL. M.Changing Views of the Role of Matrix Metalloproteinases in Metastasis. J. Natl. Cancer. Inst.89, 1260–1270 (1997).
2.
DeryuginaE. I.SoroceanuL.StronginA. Y.Up-regulation of Vascular Endothelial Growth Factor by Membrane-type 1 Matrix Metalloproteinase Stimulates Human Glioma Xenograft Growth and Angiogenesis. Cancer Res.62, 580–588 (2002).
3.
O'ReillyM. S.WiederschainD.Stetler-StevensonW. G.FolkmanJ.MosesM. A.Regulation of Angiostatin Production by Matrix Metalloproteinase-2 in a Model of Concomitant Resistance. J. Biol. Chem.274, 29568–29571 (1999).
McCawleyL. J.MatrisianL. M.Matrix Metalloproteinases: They're Not Just for Matrix Anymore!Curr. Opin. Cell. Biol.13, 534–540 (2001).
6.
OrlandoS.SironiM.BianchiG.DrummondA. H.BoraschiD.YabesD.MantovaniA.Role of Metalloproteases in the Release of the IL-1 Type II Decoy Receptor. J. Biol. Chem.272, 31764–31769 (1997).
7.
SuzukiM.RaabG.MosesM. A.FernandezC. A.KlagsbrunM.Matrix Metalloproteinase-3 Releases Active Heparin-binding EGF-like Growth Factor by Cleavage at a Specific Juxtamembrane Site. J. Biol. Chem.272, 31730–31737 (1997).
8.
DaldrupH. E.ShamesD. M.HusseiniW.WendlandM. F.OkuhataY.BraschR. C.Quantification of the Extraction Fraction for Gadopentetate Across Breast Cancer Capillaries. Magn. Reson. Med.40, 537–543 (1998).
9.
PhamC. D.RobertsT. P.van BruggenN.MelnykO.MannJ.FerraraN.CohenR. L.BraschR. C.Magnetic Resonance Imaging Detects Suppression of Tumor Vascular Permeability after Administration of Antibody to Vascular Endothelial Growth Factor. Cancer Investigation16, 225–230 (1998).
10.
GossmannA.HelbichT. H.MesianoS.ShamesD. M.WendlandM. F.RobertsT. P.FerraraN.JaffeR. B.BraschR.C.Magnetic Resonance Imaging in an Experimental Model of Human Ovarian Cancer Demonstrating Altered Microvascular Permeability after Inhibition of Vascular Endothelial Growth Factor. American Journal of Obstetrics and Gynecology183, 956–963 (2000).
11.
GossmannA.HelbichT. H.KuriyamaN.OstrowitzkiS.RobertsT. P.ShamesD. M.van BruggenN.WendlandM. F.IsraelM. A.BraschR. C.Dynamic Contrast-enhanced Magnetic Resonance Imaging as a Surrogate Marker of Tumor Response to Anti-angiogenic Therapy in a Xenograft Model of Glioblastoma Multiforme. J. Magn. Reson. Imaging.15, 233–240 (2002).
12.
TuretschekK.PredaA.FloydE.ShamesD. M.NovikovV.RobertsT. P.WoodJ. M.FuY.CarterW. O.BraschR. C.MRI Monitoring of Tumor Response Following Angiogenesis Inhibition in an Experimental Human Breast Cancer Model. Eur. J. Nucl. Med. Mol. Imaging30, 448–455 (2003).
13.
ShalinskyD. R.BrekkenJ.ZouH.McDermottC. D.ForsythP.EdwardsD.MargosiakS.BenderS.TruittG.WoodA.VarkiN. M.AppeltK.Broad Antitumor and Antiangiogenic Activities of AG3340, A Potent and Selective MMP Inhibitor Undergoing Advanced Oncology Clinical Trials. Annals of the New York Academy of Sciences878, 236–270 (1999).
14.
ShalinskyD. R.BrekkenJ.ZouH.BloomL. A.McDermottC. D.ZookS.VarkiN. M.AppeltK.Marked Antiangiogenic and Antitumor Efficacy of AG3340 in Chemoresistant Human Non-small Cell Lung Cancer Tumors: Single Agent and Combination Chemotherapy Studies. Clinical Cancer Research5, 1905–1917 (1999).
15.
SantosO.McDermottC. D.DanielsR. G.AppeltK.Rodent Pharmacokinetic and Anti-tumor Efficacy Studies with a Series of Synthetic Inhibitors of Matrix Metalloproteinases. Clin. Exp. Metastasis15, 499–508 (1997).
16.
BrinkleyB. R.BeallP. T.WibleL. J.MaceM. L.TurnerD. S.CailleauR. M.Variations in Cell Form and Cytoskeleton in Human Breast Carcinoma Cells In Vitro. Cancer Res.40, 3118–3129 (1980).
17.
PriceJ. E.PolyzosA.ZhangR. D.DanielsL. M.Tumorigenicity and Metastasis of Human Breast Carcinoma Cell Lines in Nude Mice. Cancer Res.50, 717–721 (1990).
18.
BenderS.Structure-based Design of MMP Inhibitors: Discovery and Development of AG3340. 214th National Meeting of the American Chemical Society Las Vegas, NV (1997).
19.
OganM. D.SchmiedlU.MoseleyM. E.GroddW.PaajanenH.BraschR. C.Albumin Labeled with Gd-DTPA. An Intravascular Contrast-enhancing Agent for Magnetic Resonance Blood Pool Imaging: Preparation and Characterization. Invest. Radiol.22, 665–671 (1987).
20.
SchmiedlU.OganM. D.MoseleyM. E.BraschR. C.Comparison of the Contrast-enhancing Properties of Albumin-(Gd-DTPA) and Gd-DTPA at 2.0 T: And Experimental Study in Rats. AJR Am. J. Roentgenol.147, 1263–1270 (1986).
21.
SchmiedlU.BraschR. C.OganM. D.MoseleyM. E.Albumin Labeled with Gd-DTPA. An Intravascular Contrast-enhancing Agent for Magnetic Resonance Blood Pool and Perfusion Imaging. Acta. Radiol. Suppl.374, 99–102 (1990).
22.
SchwickertH. C.RobertsT. P.ShamesD. M.van DijkeC. F.DisstonA.MuhlerA.MannJ. S.BraschR. C.Quantification of Liver Blood volume: Comparison of Ultra Short TI Inversion Recovery Echo Planar Imaging (ULSTIR-EPI), with Dynamic 3D-gradient Recalled Echo Imaging. Magnetic Resonance in Medicine34, 845–852 (1995).
23.
RobertsT. P.Physiologic Measurements by Contrast-enhanced MR Imaging: Expectations and Limitations. J. Magn. Reson. Imaging7, 82–90 (1997).
24.
van DijkeC. F.BraschR. C.RobertsT. P.WeidnerN.MathurA.ShamesD. M.MannJ. S.DemsarF.LangP.SchwickertH. C.Mammary Carcinoma Model: Correlation of Macromolecular Contrast-enhanced MR Imaging Characterizations of Tumor Microvasculature and Histologic Capillary Density. Radiology198, 813–818 (1996).
25.
Heywang-KobrunnerS. H.Contrast-enhanced Magnetic Resonance Imaging of the Breast. Invest. Radiol.29, 94–104 (1994).
26.
DvorakH. F.BrownL. F.DetmarM.DvorakA. M.Vascular Permeability Factor/Vascular Endothelial Growth Factor, Microvascular Hyperpermeability, and Angiogenesis. Am. J. Pathol.146, 1029–1039 (1995).
27.
PriceA.ShiQ.MorrisD.WilcoxM. E.BrasherP. M.RewcastleN. B.ShalinskyD.ZouH.AppeltK.JohnstonR. N.YongV. W.EdwardsD.ForsythP.Marked Inhibition of Tumor Growth in a Malignant Glioma Tumor Model by a Novel Synthetic Matrix Metalloproteinase Inhibitor AG3340. Clinical Cancer Research5, 845–854 (1999).
28.
CoussensL. M.FingletonB.MatrisianL. M.Matrix Metalloproteinase Inhibitors and Cancer: Trials and Tribulations. Science295, 2387–2392 (2002).
29.
VeikkolaT.KarkkainenM.Claesson-WelshL.AlitaloK.Regulation of Angiogenesis via Vascular Endothelial Growth Factor Receptors. Cancer Res.60, 203–212 (2000).
